Biostage annual meeting: all four proposals pass, equity plan amended

Proposal 3 – Approval of the amendment to the Company’s Amended and Restated Equity Incentive Plan The amendment to the Company’s Amended and Restated Equity Incentive Plan was approved as follows: Votes Non-Votes 10,370,321 16,358 126 0

Proposal 4 – Approval, by Non-Binding Advisory Vote, of the Compensation of the Company’s Named Executive Officers The compensation of the Company’s named executive officers was approved, by a non-binding advisory vote, as follows: Votes Non-Votes 10,184,823 12,603 189,379 0

Proposal 2 – Ratification of the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 The ratification of the appointment of Marcum LLP as the Company’s independent registered public accounting firm was approved as follows: Votes Non-Votes 11,763,540 5,174 473 0

Proposal 1 - Election of Directors On such election of directors proposal, each of Junli He and Dr. James Shmerling were elected as Class I Directors, each for a three-year term, such term to continue until the annual meeting of stockholders in 2026 and until such Director’s successor is duly elected and qualified or until their earlier resignation or removal. Due to the plurality election, votes could only be cast in favor of or withheld from the nominee and thus votes against were not applicable. The results of the election were as follows: Name Votes Withheld Broker Non-Votes Junli He 10,377,115 9,690 1,382,382 James Shmerling 2,345,415 8,041,390 1,382,382